Illumina Adds Eli Lilly Executive to Board
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Illumina ( (ILMN) ) has provided an update.
On June 16, 2026, Illumina expanded its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., as an independent director, with the move announced on June 23, 2026. Skovronsky, Eli Lilly’s Chief Scientific and Product Officer and President of Lilly Research Laboratories, brings deep expertise in drug discovery, clinical development, and translational medicine, bolstering Illumina’s strategic capabilities in genomics, multiomics, and precision medicine while aligning with its existing non-employee director compensation framework.
Illumina’s leadership highlighted that Skovronsky’s experience managing large research portfolios and commercial products across multiple therapeutic areas is expected to strengthen the Board’s scientific and innovation oversight. His prior entrepreneurial background at Avid Radiopharmaceuticals and board service at Myriad Genetics underscore a track record at the intersection of pharmaceuticals, diagnostics, and genomics, reinforcing Illumina’s positioning in a rapidly evolving genomics-driven healthcare landscape.
The most recent analyst rating on (ILMN) stock is a Buy
with a $185.00 price target.
To see the full list of analyst forecasts on Illumina stock,
see the ILMN Stock Forecast page.
Spark’s Take on ILMN Stock
According to Spark, TipRanks’ AI Analyst, ILMN is a Outperform.
The score is driven primarily by improved financial performance and strong cash generation, reinforced by an upbeat earnings call with raised guidance and continued NovaSeq X momentum. Technicals are constructive with price above major moving averages. The main restraint is valuation (P/E ~34.5) alongside lingering top-line growth uncertainty in research markets and some balance-sheet cushioning reduction.
To see Spark’s full report on ILMN stock,
click here.
More about Illumina
Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, focused on advancing genomics and multiomics platforms to improve human health. The company serves research, clinical, and applied markets, with its products used in life sciences, oncology, reproductive health, agriculture, and other emerging segments worldwide.
Average Trading Volume: 1,665,456
Technical Sentiment Signal: Buy
Current Market Cap: $24.42B
See more data about ILMN stock on TipRanks’ Stock Analysis page.
